|
|
|
|
Entero Therapeutics Inc (NASDAQ: ENTO) |
|
Price: $0.4510
$-0.02 
-4.043%
|
| Day's High:
| $0.47
| Week Perf:
| -7.39 %
|
| Day's Low: |
$ 0.45 |
30 Day Perf: |
-18 % |
| Volume (M): |
112 |
52 Wk High: |
$ 0.93 |
| Volume (M$): |
$ 51 |
52 Wk Avg: |
$0.51 |
| Open: |
$0.46 |
52 Wk Low: |
$0.32 |
|
|
| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
5 |
| Employees |
51 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-16 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Entero Therapeutics Inc
Company Address: 777 Yamato Road, Suite 502 Boca Raton 33431 FL
Company Phone Number: 589-7020 Stock Exchange / Ticker: NASDAQ ENTO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stock Market Announcement
Published Wed, Nov 13 2024 12:00 PM UTC
In a significant development within the biopharmaceutical sector, Entero Therapeutics, Inc. (Nasdaq: ENTO), based in Boca Raton, Fla. has announced a binding term sheet for a reverse merger with Journey Therapeutics, Inc. a clinical-stage biopharmaceutical company renowned for its innovative nano-immunoconjugates (NIC) platform. The Proposed Merger, poised to alter the lands...
|
| Entero Therapeutics Inc
As the earnings season for the April to June 30, 2024 period unfolds, numerous corporations in the Major Pharmaceutical Preparations sector are announcing their financial results. Entero Therapeutics Inc. (NASDAQ: ENTO), a notable player in the biopharmaceutical landscape, has reported a significant operating loss of $3.43 million for the second quarter of 2024. This marks a notable deterioration compared to the same period last year, raising questions about the company's operational efficiency and future profitability.In conjunction with the net loss of $8.81 million during the recent fiscal period, Entero Therapeutics is clearly navigating a challenging landscape as it seeks to advance its product offerings while still in the critical expansion stage of its business cycle. Such circumstances are common in the biopharmaceutical realm, where companies often endure tough fiscal challenges while developing their innovative therapies. In particular, Entero is focusing on novel solutions for gastrointestinal diseases?a market with burgeoning potential but fraught with competition and high development costs.
|
| Shares
Published Fri, Aug 23 2024 9:00 PM UTC
Entero Therapeutics, Inc. (NASDAQ: ENTO), a renowned clinical-stage biopharmaceutical company specializing in targeted therapies for gastrointestinal (GI) diseases, recently announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (Nasdaq). The letter outlined the company s non-compliance with Nasdaq Listing Rule 525...
|
| Management Announcement
Published Wed, Jul 31 2024 11:00 AM UTC
ever: Entero Therapeutics Latiglutenase on Track for Breakthrough in GI Disease Treatment
In a recent business update shared by Entero Therapeutics, Chairman and CEO James Sapirstein highlighted the promising progress in the development of their flagship product, Latiglutenase. As a clinical-stage biopharmaceutical company specializing in targeted therapies for gastroin...
|
| Clinical Study
Published Thu, Jun 27 2024 10:00 AM UTC
Entero Therapeutics, a leading biotechnology company specializing in gastrointestinal disorders, has recently published a ground-breaking research paper in a peer-reviewed journal, unveiling a novel algorithm that revolutionizes the measurement of intestinal damage in patients with Celiac Disease. This breakthrough comes as a significant advancement in the field, providing a...
|
| Per Share |
Current |
| Earnings (TTM) |
-4.99 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
0.01 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-4.99 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
0.01 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
